Literature DB >> 8880071

Alpha 2-adrenoceptor subtypes in the human brain: a pharmacological delineation of [3H]RX-821002 binding to membranes and tissue sections.

B Grijalba1, L F Callado, J Javier Meana, J A García-Sevilla, A Pazos.   

Abstract

In order to study the characterization and localization of [3H]RX-821002 (2-methoxy-idazoxan) binding to alpha 2-adrenoceptor subtypes in several regions of the human brain, we have carried out competition studies using both autoradiography and membrane binding assays. The alpha 2A-adrenoceptor subtype was found to be predominant in the different layers of the frontal cortex, cerebellum and hippocampal formation, while in the neostriatum it was the non-alpha 2A- (alpha 2B- and alpha 2C-) adrenoceptor subtype. In the frontal cortex, in addition to binding to the alpha 2A-adrenoceptor subtype, [3H]RX-821002 bound also to a small portion of alpha 2B- and alpha 2C-adrenoceptors in layer III, and to an unidentified binding site in the external layers. In the hippocampus, both alpha 2A- and non-alpha 2A- (alpha 2B- and alpha 2C-) adrenoceptors were labelled in the dentate gyrus and the CA1 field, together with 5-HT1A receptors. 5-HT1A receptors were labelled predominantly in the stratum pyramidale layer. These results, in addition to delineate the relative presence of alpha 2-adrenoceptor subtypes, indicate that caution is needed when analyzing RX 821002 binding to human brain tissue.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8880071     DOI: 10.1016/0014-2999(96)00381-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Neuron specific alpha-adrenergic receptor expression in human cerebellum: implications for emerging cerebellar roles in neurologic disease.

Authors:  U B Schambra; G B Mackensen; M Stafford-Smith; D E Haines; D A Schwinn
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

2.  Guanfacine produces differential effects in frontal cortex compared with striatum: assessed by phMRI BOLD contrast.

Authors:  Neil Easton; Yasmene B Shah; Fiona H Marshall; Kevin C Fone; Charles A Marsden
Journal:  Psychopharmacology (Berl)       Date:  2006-10-03       Impact factor: 4.530

3.  Non-adrenergic binding of [3H]atipamezole in rat kidney--regional distribution and comparison to alpha2-adrenoceptors.

Authors:  B Sjöholm; J Lähdesmäki; K Pyykkö; M Hillilä; M Scheinin
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

4.  Brain alpha(2)-adrenoceptors in monoamine-depleted rats: increased receptor density, G coupling proteins, receptor turnover and receptor mRNA.

Authors:  C Ribas; A Miralles; X Busquets; J A García-Sevilla
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

5.  Amphetamine decreases α2C-adrenoceptor binding of [11C]ORM-13070: a PET study in the primate brain.

Authors:  Sjoerd J Finnema; Zoë A Hughes; Merja Haaparanta-Solin; Vladimir Stepanov; Ryuji Nakao; Katarina Varnäs; Andrea Varrone; Eveliina Arponen; Päivi Marjamäki; Katariina Pohjanoksa; Lauri Vuorilehto; Phebian A Babalola; Olof Solin; Sarah Grimwood; Jukka Sallinen; Lars Farde; Mika Scheinin; Christer Halldin
Journal:  Int J Neuropsychopharmacol       Date:  2014-12-13       Impact factor: 5.176

6.  Differential brain ADRA2A and ADRA2C gene expression and epigenetic regulation in schizophrenia. Effect of antipsychotic drug treatment.

Authors:  Iria Brocos-Mosquera; Patricia Miranda-Azpiazu; Carolina Muguruza; Virginia Corzo-Monje; Benito Morentin; J Javier Meana; Luis F Callado; Guadalupe Rivero
Journal:  Transl Psychiatry       Date:  2021-12-20       Impact factor: 6.222

Review 7.  Neuroprotection in late life attention-deficit/hyperactivity disorder: A review of pharmacotherapy and phenotype across the lifespan.

Authors:  Cintya Nirvana Dutta; Leonardo Christov-Moore; Hernando Ombao; Pamela K Douglas
Journal:  Front Hum Neurosci       Date:  2022-09-26       Impact factor: 3.473

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.